5DG.SG,0P0001KDQK,0 (5DG.SG)
- PR Newswire
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship
On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. The scope of the agreement will also cover areas of R&D, manufacturing and commercialization in China. In connection w
- PR Newswire
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue of RMB 168 million, representing a year-on-year increase of 61.6%. The gross margin was 59.2%, and the adjusted loss amounted to RMB 101 million, narrowing by 20.0% year-on-year. This significant growth in performance is attributed to the accelerated advancement
- Simply Wall St.
3 SEHK Stocks Including Ocumension Therapeutics Estimated To Be Trading Below Intrinsic Value
The Hong Kong market has recently experienced mixed performance, with the Hang Seng Index declining by 0.45% amid weak manufacturing data and concerns over domestic demand. This presents a potential opportunity for discerning investors to identify undervalued stocks that may be trading below their intrinsic value. In light of current market conditions, focusing on stocks with strong fundamentals and growth potential can be particularly advantageous. Here are three SEHK stocks, including...
